USAQ QHSLab Inc (QB)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (date of earliest event reported): September 17, 2024

 

QHSLab, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

0-19041

(Commission File No.)

 

Nevada		30-1104301
(State of Incorporation)		(I.R.S. Employer Identification No.)
901 Northpoint Parkway Suite 302 West Palm Beach FL 33407		33407
(Address of Principal Executive Offices)		(ZIP Code)

 

Registrant’s telephone number, including area code: (929) 379-6503

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

 

Securities registered pursuant to Section 12(g) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value		USAQ		N/A

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On September 17, 2024, QHSLab, Inc. (the “Company”) issued a press release announcing Major Research and Development Milestones for 2024: Doubling Assessment Completion and Advancing Digital Medicine Innovation. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Current Report on Form 8-K (including the exhibit) is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information in the Report that is required to be disclosed solely by Regulation FD.

 

We do not have, and expressly disclaim, any obligation to release publicly any updates or any changes in our expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based.

 

We use, and will continue to use, our website (https://usaqcorp.com), press releases, and various social media channels, including our Twitter account (https://twitter.com/qhslabinc), LinkedIn account (https://www.linkedin.com/company/65407282/), Facebook account (https://www.facebook.com/QHSLabs) and Instagram account (https://www.instagram.com/qhslabs/) as additional means of disclosing public information to investors, the media and others interested in the Company. It is possible that certain information we post on our website, disseminate in press releases and on social media could be deemed to be material information, and we encourage investors, the media and others interested in the Company to review the business and financial information that we post on our website, disseminate in press releases and on the social media channels identified above, as such information could be deemed to be material information.

 

Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS

 

(d) Exhibits.

 

The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.

 

Exhibit No.		Description
99.1		Press Release dated September 17, 2024 – QHSLab Announces Major Research and Development Milestones for 2024: Doubling Assessment Completion and Advancing Digital Medicine Innovation
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

SIGNATURES

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this current report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: September 17, 2024
QHSLab, Inc.
	/s/ Troy Grogan
Name:	Troy Grogan
Title:	CEO and Chairman

 

 

 

Exhibit 99.1

 

 

 

QHSLab Announces Major Research and Development Milestones for 2024: Doubling Assessment Completion and Advancing Digital Medicine Innovation

 

WEST PALM BEACH, FL, September 17, 2024 (GLOBE NEWSWIRE) — QHSLab, Inc. (the “Company”) (OTCQB: USAQ), a leader in digital health and point-of-care technologies designed to empower clinicians with proactive, value-based healthcare solutions, today shared exciting updates on its Research & Development (R&D) activities, and patient outcomes for the year to date. The Company continues advancing healthcare technology by integrating AI-driven digital tools designed to improve clinical decision-making and patient care.

 

Year-to-date as of September 2024, QHSLab’s platform has processed approximately 50,000 assessments, more than doubling the number of assessments completed during the same period last year. This represents a meteoric rise in assessment completions with the Company quickly bringing the total number of completed assessments to the 100K milestone, supporting routine clinical use and ongoing research into allergy, depression, anxiety, and chronic pain.

 

“Our robust real-world data collection and innovative technologies have enabled us to drive meaningful improvements in patient outcomes, addressing both physical and mental health at the point of care,” said Marcos Sanchez-Gonzalez, MD, PhD, VP of Medical & Scientific Affairs at QHSLab. “The significant progress we’ve made in understanding the link between allergic rhinitis and mental health conditions like anxiety and depression demonstrates our commitment to advancing holistic care solutions for the patients served by the medical practices we support through their use of our QHSLab platform.”

 

Research & Development Initiatives

 

QHSLab’s R&D efforts remain focused on advancing digital medicine technologies that empower healthcare providers and enhance patient engagement. With a commitment to addressing chronic conditions like allergic rhinitis, anxiety, and depression, the Company continues to explore critical connections between mental and physical health.

 

“In 2024, our R&D program is pushing new boundaries in innovation. We are committed to reducing the non-clinical burden on providers while improving the overall patient experience and outcomes,” said Troy Grogan, President and CEO of QHSLab. “The unprecedented growth in assessment completions this year underscores the value of our platform and its ability to drive impactful, data-driven care.”

 

Publications, Abstracts, and Ongoing Research

 

QHSLab is proud to announce that two key abstracts have been accepted for presentation at the American College of Allergy, Asthma, and Immunology (ACAAI) conference in Boston next month. These abstracts showcase the unique capabilities of the QHSLab platform in allergy management and its connection to mental health outcomes:

 

	1.	Longitudinal Study: The impact of help-seeking behaviors on allergic rhinitis and mental health outcomes
	2.	Cross-Sectional Study: The association between poor allergy control and increased depression and anxiety symptoms

 

These studies, which are part of the Company’s enhanced real-world data capture capabilities, highlight significant findings linking allergic rhinitis to mental health outcomes, including improved SNOT-22 and PHQ-GAD16 scores for patients actively seeking care for their allergies and emotional well-being.

 

Additionally, QHSLab has submitted two abstracts for poster presentations at the 2025 American Psychiatric Association Annual Meeting, which focus on the Company’s latest digital therapeutic interventions for mental health and chronic pain. These abstracts explore the effectiveness of QHSLab’s digital platform in reducing symptoms of anxiety, depression, and chronic pain through integrated care. Preliminary findings suggest that users of the Company’s QHSLab health journeys series report lower levels of depression, anxiety, pain, and allergy scores after using the resources for just a few months. Although the findings are promising, the Company is not jumping to conclusions. The Company has ongoing R&D efforts to understand better the therapeutic potential of using the QHSLab health journeys resources - more to come.

 

 

Looking Ahead

 

QHSLab continues to leverage its vast real-world data and innovative digital platform to expand research on the interconnections between physical and mental health, exploring new avenues for delivering high-quality, patient-centered care. With more assessments being conducted daily and ongoing studies in allergy, anxiety, depression, and chronic pain, QHSLab remains at the forefront of transforming healthcare.

 

For more information about QHSLab and its digital health solutions, please visit qhslab.com.

 

About QHSLab, Inc.

 

QHSLab, Inc. (OTCQB: USAQ) is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare allows doctors to assess patient responses quickly and effectively using advanced artificial intelligence algorithms. Digital healthcare can also remotely monitor patients’ vital signs and evaluate the effects of prescribed medicines and treatments on patients’ health through real-time data transferred from patient to doctor. QHSLab, Inc. also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. QHSLab, Inc.’s products and services are designed to help physicians improve patient monitoring and medical care while also improving their revenues.

 

Forward-Looking Statements

 

Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends,’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

 

Investor Relations Contact:

 

Olivia Giamanco

QHSLab, Inc.

(929) 379-6503

ir@usaqcorp.com

https://twitter.com/QHSLabInc

 

 

v3.24.3

Cover	Sep. 17, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Sep. 17, 2024
Entity File Number	0-19041
Entity Registrant Name	QHSLab, Inc.
Entity Central Index Key	0000856984
Entity Tax Identification Number	30-1104301
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	901 Northpoint Parkway
Entity Address, Address Line Two	Suite 302
Entity Address, City or Town	West Palm Beach
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33407
City Area Code	(929)
Local Phone Number	379-6503
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	USAQ

---